REG - Ergomed plc - Block Listing Six Monthly Return
RNS Number : 7694LErgomed plc02 January 2019BLOCK LISTING SIX MONTHLY RETURN
Date: 2 January 2019
Name of applicant:
Ergomed plc
Name of scheme:
Ergomed plc Long Term Incentive Plan
Period of return:
From:
2 July 2018
To:
31 December 2018
Balance of unallotted securities under scheme(s) from previous return:
1,800,000 (original admission)
Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):
nil
Less: Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G):
55,000
Equals: Balance under scheme(s) not yet issued/allotted at end of period:
1,745,000
Number and class of securities originally admitted and the date of admission
1,800,000 ordinary shares of 1p each - 2 July 2018
Total number of securities in issue at the end of the period
45,016,438 ordinary shares of 1p each
Name of contact:
Nick Blech - Deputy CFO
Telephone number of contact:
+44 (0)7768 547372
Enquiries:
Ergomed plc
Tel: +44 (0) 1483 503205
Stephen Stamp (Chief Executive Officer)
Stuart Jackson (Chief Financial Officer)
Numis Securities Limited
Tel: +44 (0) 20 7260 1000
Michael Meade / Freddie Barnfield (Nominated Adviser)
James Black (Broker)
Consilium Strategic Communications - for UK enquiries
Tel: +44 (0) 20 3709 5700
Chris Gardner / Mary-Jane Elliott
Matthew Neal / Olivia Manser
ergomed@consilium-comms.com
MC-Services - for Continental European enquiries
Tel: +49 211 5292 5222
Anne Hennecke
About Ergomed plc
Ergomed provides specialist services to the pharmaceutical industry spanning all phases of clinical development, post-approval pharmacovigilance and medical information. Ergomed's fast-growing, profitable services offering encompasses a complete suite of specialist pharmacovigilance solutions, integrated under the PrimeVigilance brand, in addition to a full range of high quality contract research and trial management services (CRO). Leveraging its CRO expertise, Ergomed also has a drug development portfolio of co-development partnerships and wholly-owned programmes. For further information, visit: http://ergomedplc.com
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.ENDBLRFEWFWAFASEEE
Recent news on Ergomed
See all newsREG - Ergomed plc - Cancellation of admission to trading of shares
AnnouncementREG - AIM Ergomed plc - Cancellation - Ergomed plc
AnnouncementREG - Takeover Panel - Disclosure Table
AnnouncementREG-Millennium Partners, L.P. Form 8.3 - Ergomed plc
AnnouncementREG - BlackRock Group Ergomed plc - Form 8.3 - Ergomed plc
Announcement